CJC-1295 No DAC vs. Ipamorelin: Research Peptide Comparison

CJC-1295 No DAC and Ipamorelin are the two most-cited growth-hormone-axis research peptides of the past two decades. They are routinely discussed together because they target complementary signaling pathways — but they are not interchangeable, and the published research that supports each is distinct. This comparison covers what differs and why most researchers run them as a stack.

Published February 8, 2026 · Reviewed by Dr. Marina Voss, PhD (Senior Research Reviewer)

Quick comparison

	CJC-1295 No DAC	Ipamorelin
Receptor target	GHRH receptor (growth-hormone-releasing-hormone receptor)	GHS-R (growth-hormone-secretagogue receptor / ghrelin receptor)
Peptide length	29 amino acids (modified GRF 1-29)	5 amino acids (pentapeptide)
Reported plasma half-life	~30 minutes (short-acting)	~2 hours
Key publications	JCEM 2006 (PMID 16384879), Endocr Rev 2012 (PMID 22148949)	Eur J Endocrinol 1998 (PMID 9849822), Growth Horm IGF Res 2008 (PMID 18430761)
Selectivity profile	GHRH-receptor agonist	Selective GHS-R agonist — research suggests reduced cortisol/prolaktin activity vs. earlier GHRPs
Commonly studied stack partner	Ipamorelin	CJC-1295 No DAC
Pre-blended SKU at BioInfinity Lab	Yes — /buy/cjc-1295-ipamorelin	Yes — /buy/cjc-1295-ipamorelin

Verdict: These two peptides target complementary growth-hormone-release pathways and are most often studied together rather than in isolation. For researchers running combined protocols, the pre-blended /buy/cjc-1295-ipamorelin vial removes one procurement step. For researchers studying one pathway in isolation, single-compound vials remain available at /buy/cjc-1295-no-dac and /buy/ipamorelin.

Buy CJC-1295 No DAC →Buy Ipamorelin →

Why the two peptides are routinely studied together

Published growth-hormone-axis literature describes two complementary stimulation pathways: GHRH-receptor agonism (the pathway CJC-1295 No DAC targets) and GHS-R / ghrelin-receptor agonism (the pathway Ipamorelin targets). Research suggests that engaging both pathways simultaneously produces a more pulsatile, more physiological-style growth-hormone-release pattern in research models than either pathway alone.

This is why most research protocols cite the combination — single-pathway protocols are less common in the peer-reviewed literature.

CJC-1295 No DAC vs. CJC-1295 DAC — which one researchers use

CJC-1295 is available in two research forms: with DAC (Drug Affinity Complex, extending serum half-life into days) and without DAC (short serum half-life, around 30 minutes). Modern research protocols predominantly use the No DAC variant because the short half-life supports physiological-style pulsatile GHRH-receptor stimulation rather than continuous receptor engagement. BioInfinity Lab stocks the No DAC variant at /buy/cjc-1295-no-dac.

Ipamorelin's selectivity — what makes it distinct from earlier GHRPs

The 1998 publication that introduced Ipamorelin (Raun et al., Eur J Endocrinol, PMID 9849822) characterized it as a selective growth-hormone secretagogue with reduced reported activity on cortisol and prolaktin compared to earlier GHRP-family compounds (GHRP-2, GHRP-6). This selectivity is the central reason most modern research protocols favor Ipamorelin over those earlier compounds when investigating GHS-R-mediated pathways.

Dosing and protocol design in published research

Research protocols commonly cite microgram-per-kilogram dose ranges for both compounds in animal-model studies, with the two administered concurrently for combined-protocol research. Researchers should refer to the cited publications for specific dose-escalation schedules and follow their IRB-approved protocols.

For researchers running combined protocols, BioInfinity Lab's pre-blended vial at /buy/cjc-1295-ipamorelin contains precisely-weighed quantities of both compounds in a single vial.

Frequently asked questions

Quick answers about the CJC-1295 No DAC vs Ipamorelin comparison.

Why do researchers run CJC-1295 and Ipamorelin together?+

The two compounds target complementary pathways — GHRH receptor and GHS-R receptor. Combined administration is described in published research as producing more pulsatile, more physiological growth-hormone-release patterns than either compound alone.

Should I use CJC-1295 No DAC or CJC-1295 DAC?+

Most modern research protocols use the No DAC variant because its short serum half-life supports pulsatile, physiological-style GHRH-receptor stimulation. The DAC variant's days-long half-life is less suited to pulsatile research models.

Is the pre-blended vial different from buying the two separately?+

Functionally no — the pre-blended vial contains precisely-weighed quantities of both compounds in a single vial. It saves a procurement and reconstitution step for researchers running combined protocols.

For laboratory research use only. Not for human or veterinary use. Content is informational and does not constitute medical advice.